FATE
Fate Therapeutics, Inc.
$2.11
+0.96%
2026-10-23
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-2.43
EPS (TTM)
$-1.05
ROE
-60.8%
Revenue Growth (YoY)
9.2%
Profit Margin
0.0%
Debt/Equity
49.32
Price/Book
1.79
Beta
2.55
Market Cap
$281.6M
Avg Volume (10D)
1.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$2.88
60D Low
$1.75
Avg Volume
1.6M
Latest Close
$2.11
Get breakout alerts for FATE
Sign up for Breakout Scanner to receive daily notifications when FATE triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Fate Therapeutics, Inc. (FATE) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors FATE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. FATE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.